Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;22(4):447.
doi: 10.1016/S1473-3099(22)00120-7.

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply

Ramachandran Thiruvengadam  1 , Amit Awasthi  1 , Shinjini Bhatnagar  1 , Pramod Kumar Garg  2 ; DBT Consortium for COVID-19 Research
Affiliations
Comment

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply

Ramachandran Thiruvengadam et al. Lancet Infect Dis. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

References

    1. Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(21)00680-0. published online Nov 25. - DOI - PMC - PubMed
    1. Jordan SC, Shin B-H, Gadsden TM, et al. T cell immune responses to SARS-CoV-2 and variants of concern (alpha and delta) in infected and vaccinated individuals. Cell Mol Immunol. 2021;18:2554–2556. - PMC - PubMed
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime–boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. - PMC - PubMed
    1. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501. - PMC - PubMed
    1. WHO . World Health Organization; Geneva: 2021. Evaluation of COVID-19 vaccine effectiveness.https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccine_e...

Substances